An optimized BRCA1/2 next-generation sequencing for different clinical sample types.

CONCLUSIONS: On the comparison of the analytical performance according to different sample types, the buffy coat was not affected by sequencing artifacts and VAF shifted variants. Therefore, the blood test should be given priority in detecting germline BRCA1/2 mutation, and tumor materials could be suitable to detect somatic mutations in OC patients without identifying germline BRCA1/2 mutation. PMID: 31788999 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31788999?dopt=Abstract

Source: Journal of Gynecologic Oncology - December 4, 2019 Category: OBGYN Tags: J Gynecol Oncol Source Type: research